Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer

Clinical trial NCT07303881 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07303881
Sponsor: The First Affiliated Hospital of Guangzhou Medical University
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

IrAE Hematologic Disorder Lung Cancer (Locally Advanced or Metastatic)

Start date: 2026-02-01
Primary completion: 2027-06-01
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.